The Indian diaspora is showing strong confidence in the Indian economy, with NRI deposit inflows more than doubling to $7.8 billion from April to August this year, compared to $3.7 billion in the same period last year, according to the Reserve Bank of India.
CD&R makes Rs 2,983 cr offer for 26% stake in Sanofi Consumer Healthcare (21-10-2024)
Global investment firm CD&R on Monday announced an open offer to acquire a 26 per cent stake in Sanofi Consumer Healthcare India Ltd for an aggregate of up to Rs 2,983 crore.
The development follows Sanofi and Clayton, Dubilier & Rice (CD&R) entering into exclusive negotiations whereby CD&R Group has agreed to acquire a controlling stake in Opella, which holds a 60.4 per cent stake in Sanofi Consumer Healthcare India.
The offer is made at a price of Rs 4,982.05 per share, aggregating to a total consideration of up to Rs 2,983.23 crore, according to the offer letter by Citigroup Global Markets India, the manager of the transaction, shared on BSE by Sanofi Consumer Healthcare India.
The open offer has been triggered by Sanofi and CD&R entering into exclusive negotiations for the potential sale and purchase of a 50 per cent controlling stake in Opella, Sanofi’s consumer healthcare division.
The valuation of Opella is based on an enterprise value of 16 billion …
Mahindra Logistics Q2 Results: Profit falls 54% to Rs 8.5 crore (21-10-2024)
Mahindra Logistics Ltd reported a 54% decline in standalone PAT to Rs 8.5 crore for Q2 FY25, despite a 9% revenue increase to Rs 1,236 crore. Strong growth was seen in 3PL logistics, cross border, and last mile delivery segments, with future expectations optimistic due to investments and the festive season peak.
Rupee closes at record low of 84.0725 against US dollar on outflows, strong dollar index (21-10-2024)
The Indian rupee hit a record low of 84.0725 against the US dollar, driven by outflows from local equities and debt, and Hyundai’s fund repatriation. The Reserve Bank of India’s likely intervention helped limit further losses, while fluctuations in the dollar index ahead of US elections also influenced the rupee’s performance.
NPST – Technology Provider for UPI Tech (21-10-2024)
joined the call. Didn’t get a chance to raise the 2 questions i had noted.
- My question is with regard to evok/ppas segment. Kindly explain in layman terms, how the revenue flows to NPST for this segment. Like who pays to NPST, and one level up the chain, who pays to the ‘payer to NPST’ and so on. This question comes from concerns around 2 topics. a. Govt. reducing incentives for digital payments ( are we a big beneficiary of that?) b. Reports around merchants not willing to pay MDR to for upi payments.
- My understanding so far is, the evok transaction volume are a subset of cosmos payee PSP nos. and mgmt. had also hinted the same in earlier calls. But we see that comsos payee PSP nos. as reported by NPCI website have seen a sharp decline in last 2 months. In fact cosmos has gone from being in Top 10 to out of Top 15 rankings in psp volumes. But as of Q225 we don’t see this impact evok nos. significantly. Has anything changed on ground which investors should worry about? How would you define the relation between cosmos payee PSP nos. vs evok transaction volume.
Call recording is already available on youtube. Apart from normal updates around product development, one significant update is, Mgmt spoke about on-boarding 2 more sponsor banks in addition to cosmos. Could this be already in action and hence we see the impact on cosmos nos. ?
CD&R makes Rs 2,983 cr open offer for 26% stake in Sanofi Consumer Healthcare India (21-10-2024)
Global investment firm CD&R announces an open offer to acquire a 26% stake in Sanofi Consumer Healthcare India for up to Rs 2,983 crore. This follows exclusive negotiations to acquire a controlling stake in Opella. The offer price is Rs 4,982.05 per share, aiming to secure 60.4% voting rights after the deal completion.
Jana Small Finance Bank Q2 Results: Net profit slides 21% YoY to Rs 97 crore (21-10-2024)
The bank’s non-performing assets ratio increased to 2.97% in September, up from 2.44% a year earlier. Provisions rose to Rs 210 crore from Rs 160 crore, impacting net profit. Pre-provision operating profit reached Rs 299 crore, slightly above last year’s Rs 283 crore, while net interest income increased to Rs 594 crore from Rs 526 crore.
Stable trend in financials crucial for Godavari Biorefineries (21-10-2024)
Godavari Biorefineries aims to raise Rs 555 crore through an IPO scheduled for October 23-25, 2024. The funds will be used to repay debt and for an offer for sale. The promoter stake will drop from 81% to over 63%. The company produces sugar, ethanol, and bio-based chemicals, with significant market presence in these sectors.